Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2021-04-30 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
CONNECTED TRANSACTION - DISPOSAL OF 49.5% EQUITY INTEREST IN JOINT VENTURE COMPANY /CONTINUING CONNECTED TRANSACTIONS - MASTER PURCHASE AGREEMENT
Regulatory Filings Classification · 95% confidence The document is an announcement by CSPC Pharmaceutical Group Limited regarding a connected transaction involving the disposal of a 49.5% equity interest in a joint venture company and a continuing connected transactions master purchase agreement. It references compliance with Chapter 14A of the Hong Kong Listing Rules, discusses percentage ratios under Rule 14.07, and details the terms, reasons, and financial effects of the disposal and the master purchase agreement. The document is lengthy (15,000 characters) and contains detailed transaction information, but it is clearly an announcement of corporate transactions rather than a financial report or earnings release. It does not contain financial statements or quarterly results but focuses on connected transactions and related disclosures. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-04-30 English
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2021
Interim / Quarterly Report Classification · 95% confidence The document is an announcement by CSPC Pharmaceutical Group Limited regarding the principal financial information of its subsidiary CSPC Innovation Pharmaceutical Co., Ltd. for the three months ended 31 March 2021. It references the subsidiary's 2021 First Quarterly Report published on the Shenzhen Stock Exchange website. The document includes detailed financial data such as revenue, net profit, cash flows, and explanations for significant changes in accounting data and financial indicators. The presence of comprehensive financial statements and detailed analysis for a quarterly period indicates this is a substantive financial report for a period shorter than a full fiscal year. The document is not merely an announcement of a report's publication but contains actual financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-04-26 English
VOLUNTARY ANNOUNCEMENT - NBL-012 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a new drug (NBL-012) by the National Medical Products Administration (NMPA) of China. It contains no financial data, no detailed financial performance, no management discussion of financial results, and no regulatory certifications or voting results. The document is relatively short (4040 characters) and serves as an announcement of a significant corporate development related to drug approval and clinical trials. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement since it does not mention any report being attached or published. The content is best classified as a general corporate announcement about a clinical trial approval, which falls under the fallback category Regulatory Filings (RNS) as it does not fit any other specific category.
2021-04-23 English
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR MARKETING APPROVAL OF "DUVELISIB CAPSULES" ACCEPTED BY NMPA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the acceptance of an application for marketing approval of a pharmaceutical product by the National Medical Products Administration (NMPA) of China. It is a short announcement (2321 characters) that informs about regulatory progress and marketing approval status, without containing financial data, detailed financial results, or management discussion. It does not present an annual or interim report, earnings release, or any detailed financial or governance information. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-04-19 English
PROXY FORM FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, 18 MAY 2021 AT 10:00 A.M. (AND AT ANY ADJOURNMENT THEREOF)
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a proxy form for the Annual General Meeting (AGM) of CSPC Pharmaceutical Group Limited, detailing the appointment of proxies and voting instructions for resolutions to be considered at the AGM. It includes items such as receiving the audited financial statements, re-election of directors, dividend declaration, and mandates for share buy-back and issuance. This type of document is used to facilitate shareholder voting at the AGM and is not the AGM presentation materials themselves, nor is it the announcement of voting results. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length and content confirm it is not a brief announcement or a full report but a proxy form for the AGM.
2021-04-14 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a notice of the Annual General Meeting (AGM) for CSPC Pharmaceutical Group Limited. It includes details about the meeting date, agenda items such as receiving audited financial statements, re-election of directors, dividend declaration, and share buyback and issuance mandates. The document is a formal announcement inviting shareholders to attend the AGM and vote on various resolutions. It does not contain the actual annual report, financial statements, or detailed financial data, but rather the notice of the meeting where such reports will be considered. Therefore, it fits the category of AGM Information (AGM-R). The document length is over 14,000 characters, indicating it is a full notice rather than a brief announcement, supporting the classification as AGM Information rather than a simple report publication announcement or regulatory filing.
2021-04-14 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.